NCT03536104Completed
Identification of Risk Factors Parkinson's Disease by Convergence Strategy
Source: ClinicalTrials.gov · Last updated 3 Dec 2025
Brief summary (registry, in English)
Using this convergence approach from a limited group of subjects with non-diseased controls, patients with Parkinson's disease or related diseases, we will be able to limit the number of potential genes of specific susceptibility to Parkinson disease. These genes will then be studied using a case-control genetic epidemiology approach. The risk of developing the disease will then be evaluated according to clinical, biological and environmental variables collected in Parkinson's subjects and healthy controls in the second group of subjects. The specificity of the genetic associations found will be evaluated in subjects with Parkinson's disease.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 2220 (actual)
- First submitted
- 14 May 2018
- Start date
- 25 Mar 2009
- Primary completion date
- 19 Nov 2024
- Lead sponsor
- University Hospital, Lille
- Diseases
- Parkinson disease
- NCT number
- NCT03536104
What you commit to
- Study type: Observational
- Participants enrolled: 2220
- From 25 Mar 2009 to the primary completion date, 19 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in another therapeutic trial or in the exclusion period of a previous clinical trial.
- Criteria for non-inclusion of non-ill controls:
- Participation in another therapeutic trial or in the exclusion period of a previous clinical trial.
Other illness
- Clinical criteria for exclusion of the diseases described
Other
- Criteria for non-inclusion of patients:
- Functional discomfort in daily life of unknown cause
- MMSE less than 25
Who the study is looking for
- Inclusion criteria for Parkinson's patients and "related diseases" controls:
- Parkinsonian patients meeting the Gelb criteria
- Patients with other neurodegenerative disease (such as other Parkinson syndrome or synucleopathies) meeting the criteria set out in Appendix 2 (Lewy Bodies dementia, Parkinson's disease with dementia, MultiSystem atrophy, Progressive Supranuclear Paralysis) , Amyotrophic Lateral Sclerosis, Restless Legs Syndrome, Alzheimer's Disease).
- Woman of childbearing age having an effective means of contraception.
- Informed consent signed by the subject or his legal representative.
- For demented subjects coming for consultation or day hospitalization with an accompanying person, signature of the legal representative.
- Criteria for inclusion of non-ill controls:
- Absence of rest trembling, bradykinesia and stiffness
- MMSE (Mini Mental State Examination) greater than 25
- Woman of childbearing age having an effective means of contraception.
- subject having signed the informed consent.
- No family history of neurodegenerative disease that started before age 70. These controls will not present any Parkinsonian signs during the clinical evaluation. They may have functional disabilities whose cause is known and unrelated to a neurodegenerative disease with a cognitive function measurement greater than 25 in the MMSE test.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hôpital Roger Salengro (CHRU de Lille) Coordinator of this site? Confirm its status | Lille | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.